GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Other Long Term Assets

Psyence Biomedical (Psyence Biomedical) Other Long Term Assets : $0.00 Mil (As of Mar. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Other Long Term Assets?

Psyence Biomedical's other long-term assets for the quarter that ended in Mar. 2023 was $0.00 Mil.


Psyence Biomedical Other Long Term Assets Historical Data

The historical data trend for Psyence Biomedical's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Other Long Term Assets Chart

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23
Other Long Term Assets
- - -

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Mar23
Other Long Term Assets - - -

Psyence Biomedical Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.


Psyence Biomedical (Psyence Biomedical) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines